Combining STX16-targeted therapies with existing immunotherapeutic approaches could synergistically enhance anti-tumor immune responses by reducing immune evasion associated with STX16 expression and improving the overall immune landscape within the tumor microenvironment. This evidence concerns the gene STX16 and neoplasm.